New membrane technology by haemodialysis for the multiple myeloma

Abstract

technology with the potential to advance the treatment of multiple myeloma patients with acute renal failure. Gambro’s latest innovation, the High Cut-off Protein-permeable membrane HCO 1100, has the potential to significantly improve the treatment of multiple myeloma patients with Acute Renal Failure. The HCO 1100 membrane is particularly effective in dialysis treatment for the removal of nephrotoxic serum free light chains, which is a protein present at abnormally high concentrations in multiple myeloma patients and which may lead to acute renal failure. Multiple myeloma is a type of cancer that results in an overgrowth of malignant plasma cells in the bone marrow resulting in an over-production of free light chain protein. The presence of abnormally high concentrations of serum free light chains in the blood is a major cause of acute renal failure in multiple myeloma patients. Preliminary clinical investigations suggest that shortening the time during which the patient’s kidney is exposed to toxic serum free light chains can decrease the risk of developing chronic renal failure in this patient population. Initial clinical studies performed at the University of Birmingham (UK) demonstrated that the HCO 1100 membrane rapidly removes nephrotoxic serum free light chains from the blood1. This development of free light chain removal heamodialysis using the HCO 1100 (FLCR-HD) together with chemotherapy is a significant breakthrough in the treatment of multiple myeloma patients with renal failure2. The HCO 1100 membrane is specifically designed for blood purification in diseases requiring the removal of larger molecules from blood. The HCO 1100 membrane has a pore size three times greater than that of normal haemodialysis membrane. It was demonstrated in a recent study from the University of Birmingham (UK)3 and the University of Tubingen (Germany)4 that the larger membrane pores of the HCO 1100 allows for a greater removal of larger proteins, such as serum free light chains compared to a normal heamodialysis filter. To further substantiate the clinical value of the free light chain removal haemodialysis with the HCO 1100 membrane in patients with multiple myeloma, a European multi-center, randomized, controlled clinical trial is planned to start in the near future. The HCO 1100 membrane is CE Marked and available in the following 18 European countries: Ireland; Germany; Austria; Switzerland; Italy; Sweden; Spain; Finland; France; Luxembourg; Malta; Cyprus;